Literature DB >> 11030754

Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice.

G Yvert1, K S Lindenberg, S Picaud, G B Landwehrmeyer, J A Sahel, J L Mandel.   

Abstract

Among the eight progressive neurodegenerative diseases caused by polyglutamine expansions, spinocerebellar ataxia type 7 (SCA7) is the only one to display degeneration in both brain and retina. We show here that mice overexpressing full-length mutant ataxin-7[Q90] either in Purkinje cells or in rod photoreceptors have deficiencies in motor coordination and vision, respectively. In both models, although with different time courses, an N-terminal fragment of mutant ataxin-7 accumulates into ubiquitinated nuclear inclusions that recruit a distinct set of chaperone/proteasome subunits. A severe degeneration is caused by overexpression of ataxin-7[Q90] in rods, whereas a similar overexpression of normal ataxin-7[Q10] has no obvious effect. The degenerative process is not limited to photoreceptors, showing secondary alterations of post-synaptic neurons. These findings suggest that proteolytic cleavage of mutant ataxin-7 and trans-neuronal responses are implicated in the pathogenesis of SCA7.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11030754     DOI: 10.1093/hmg/9.17.2491

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

1.  Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration.

Authors:  Stephanie A Furrer; Mathini S Mohanachandran; Sarah M Waldherr; Christopher Chang; Vincent A Damian; Bryce L Sopher; Gwenn A Garden; Albert R La Spada
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

Review 2.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

Review 3.  Genetic targeting of cerebellar Purkinje cells: history, current status and novel strategies.

Authors:  Jaroslaw J Barski; Matthias Lauth; Michael Meyer
Journal:  Cerebellum       Date:  2002-04       Impact factor: 3.847

4.  Gcn5 loss-of-function accelerates cerebellar and retinal degeneration in a SCA7 mouse model.

Authors:  Yi Chun Chen; Jennifer R Gatchel; Rebecca W Lewis; Chai-An Mao; Patrick A Grant; Huda Y Zoghbi; Sharon Y R Dent
Journal:  Hum Mol Genet       Date:  2011-10-14       Impact factor: 6.150

Review 5.  Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease.

Authors:  Christian S Lobsiger; Don W Cleveland
Journal:  Nat Neurosci       Date:  2007-11       Impact factor: 24.884

Review 6.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

Review 7.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 8.  Histone acetylation, acetyltransferases, and ataxia--alteration of histone acetylation and chromatin dynamics is implicated in the pathogenesis of polyglutamine-expansion disorders.

Authors:  Shaun D McCullough; Patrick A Grant
Journal:  Adv Protein Chem Struct Biol       Date:  2010       Impact factor: 3.507

Review 9.  The ubiquitin-proteasome system in retinal health and disease.

Authors:  Laura Campello; Julián Esteve-Rudd; Nicolás Cuenca; José Martín-Nieto
Journal:  Mol Neurobiol       Date:  2013-01-22       Impact factor: 5.590

Review 10.  The eye as a window to inborn errors of metabolism.

Authors:  B T Poll-The; L J Maillette de Buy Wenniger-Prick; P G Barth; M Duran
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.